National and Kapodistrian University of Athens
Insights into cardiovascular toxicity of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in breast cancer patients
Abstract
dc:descriptionIntroduction: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative breast cancer (BC) represents the most prevalent solid malignancy among women, worldwide. Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in combination with endocrine therapy (ET) is the current gold standard treatment in the first-line for metastatic disease. Ribociclib has consistently been correlated with overall survival (OS) benefit across trials, regardless of the patient's menopausal status. Apart from the well-characterized QTc prolongation, potential cardiovascular toxicities (CVT) of ribociclib-based combos remain inadequately characterized. Aim of the study: In the present single-center, prospective, observational study, we aimed to evaluate both the incidence and spectrum of ribociclib-mediated CVT, in real-world setting, as well as to decipher the serum proteomics profile differences between those patients who experienced CVT (cases) and those who did not (controls). Patients & Methods: We prospectively recruited HR-positive/HER2-negative metastatic BC patients, who initiated ribociclib/ET combinational therapy at the Department of Clinical Therapeutics & Laboratory of Alexandra Hospital, School of Medicine, National and Kapodistrian University of Athens, Greece, during the period April 08, 2021 – March 31, 2023. Prior radiotherapy (RT) and/or systemic antineoplastic therapy were permitted, with the exception of anti-HER2 targeted agent(s). Baseline QTc ≥450 msec and uncontrolled cardiovascular comorbidities were among the exclusion criteria. Peripheral blood samples were obtained from cases within 15 days of the CVT incidence, as well as from age- and sex- matched controls, for the quantitative proteomics analysis with data-independent acquisition liquid chromatography-tandem mass spectrometry (DIA LC-MS/MS). Results: After a median follow-up of 27.2 months, 5 cases of CVT among the 62 enrolled patients (8.06%; median age: 67 years, range: 57 – 79 years) had been reported. All cases were female patients who received ribociclib as first-line therapy, with letrozole being the ET backbone in 4 (80%). 4/5 (80%), 3/5 (60%), and 1/5 (20%) had cardiovascular comorbidities, prior anthracycline-, and left-sided breast irradiation exposure, respectively. In respect to CVT spectrum, these included asymptomatic QTc prolongation, syncope, transient ischemic attack (TIA), pericardial effusion, and deep vein thrombosis (DVT), with the mean time to CVT onset being 7.56 months (range: 1.84 – 20.9 months). Permanent discontinuation of ribociclib was considered necessary for the cases of syncope and pericardial effusion. No deaths have been occurred during the study period. The proteomics analysis quantified 144 differentially expressed proteins (DEPs), of which 35 and 109 were up- and down- regulated, respectively. A detailed gene ontology (GO) functional analysis based on the statistically significant and most clinically relevant DEPs demonstrated that the negative regulation of endopeptidase activity [Lp(a), SERPINs], the phosphatidylcholine metabolism [GPLD1, APOA4, PON1], immune response [IGHGs, IGHVs, IGLVs], complement activation [IGHGs], and immunoglobulin production [IGKVs, IGLVs] signaling pathways were the most affected. Conclusion: The external validation in larger cohorts of our hypothesis-generating findings could not only significantly improve understanding of the underlying pathophysiological mechanisms of ribociclib-mediated CVT but also accelerate the development of biomarker-driven cardiovascular preventive strategies.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Fiste, Oraianthi
- Φιστέ, Ωραιάνθη
Subjects
dc:subject × 14Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/57698